Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $383.65M.
ENTERPRISE VALUE (EV)
$383.65M
BlossomHill Therapeutics, Inc.
Market Cap
$520.33M
Enterprise Value (EV)
$383.65M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $520.33M | $383.65M |
| Altimmune, Inc. (ALT)vs › | $522.16M | $494.86M |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $523.04M | $503.87M |
| Immix Biopharma, Inc. (IMMX)vs › | $526.07M | $301.58M |
| Crescent Biopharma, Inc. (CBIO)vs › | $510.36M | $340.20M |
| 908 Devices Inc. (MASS)vs › | $509.12M | $450.40M |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | $540.83M |
| Nuvectis Pharma, Inc. (NVCT)vs › | $534.18M | $512.02M |
| Delcath Systems, Inc. (DCTH)vs › | $535.43M | $490.37M |
| ProKidney Corp. (PROK)vs › | $536.32M | $464.98M |
Market Cap
$520.33M
Total Debt
$0.00
Cash
$136.68M
Enterprise Value
$383.65M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
